Baseline Characteristics | HR (95% CI) | p-value | Chemotherapy | HR (95% CI) | p-value |
---|---|---|---|---|---|
Age | 0.978 (0.958–1.000) | 0.047 | Regimen | 0.941 | |
Gender | 0.111 | Platinum + FU | 1 | ||
Male | 1 | Taxane + FU | 1.336 (0.643–2.776) | 0.437 | |
Female | 1.464 (0.916–2.339) | Platinum + Taxane + FU | 1.116 (0.569–2.188) | 0.750 | |
cT stage | 0.734 | Taxane + Platinum | 1.003 (0.511–1.969) | 0.994 | |
Serosa negative | 1 | Others | 0.904 (0.354–2.306) | 0.832 | |
Serosa positive | 1.107 (0.616–1.988) | Best response | |||
cN stage | 0.743 | Overall | 0.201 | ||
N0/N1 | 1 | CR/PR | 1 | ||
N2/N3 | 1.109 (0.597–2.061) | SD/PD | 1.359 (0.849–2.175) | ||
Type of distant metastasis | 0.065 | Local region | 0.576 | ||
Peritoneal carcinomatosis | 1 | CR/PR | 1 | ||
Liver metastasis | 0.407 (0.166–0.994) | 0.049 | SD/PD | 1.142 (0.717–1.817) | |
Distant LN metastasis | 1.025 (0.590–1.780) | 0.930 | Metastatic site | 0.013 | |
Krukenberg tumor | 4.423 (1.004–19.487) | 0.049 | CR/PR | 1 | |
Any combination | 0.900 (0.467–1.735) | 0.753 | SD/PD | 2.105 (1.171–3.783) | |
NLR (Neut/lympho) | 1.349 (0.837–2.177) | 0.219 | Preop. response | ||
SII (PLT*Neut/lympho) | 1.252 (0.776–2.019) | 0.357 | Overall | 0.635 | |
Albumin | 0.986 | CR/PR | 1 | ||
low | 1 | SD/PD | 1.119 (0.704–1.777) | ||
normal | 1.006 (0.480–2.108) | Local region | 0.875 | ||
CR/PR | 1 | ||||
SD/PD | 0.963 (0.602–1.540) | ||||
Metastatic site | 0.020 | ||||
CR/PR | 1 | ||||
SD/PD | 1.850 (1.103–3.103) | ||||
Number of Cycles of Chemotherapy | 0.970 (0.930–1.013) | 0.167 | |||
≤ 6 cycles | 1 | 0.746 | |||
> 6 cycles | 0.925 (0.578–1.480) | ||||
Pre-Operation | HR (95% CI) | p-value | Surgical Outcomes | HR (95% CI) | p-value |
BMI | 0.004 | Peritoneal infiltration | 0.002 | ||
Normal | 1 | No | 1 | ||
Underweight | 3.538 (1.607–7.789) | 0.002 | Yes | 2.181 (1.343–3.540) | |
Overweight & obese | 1.073 (0.647–1.778) | 0.786 | Metastasectomy | 0.252 | |
Change in CEA level | 0.009 | No | 1 | ||
Stable | 1 | Yes | 1.507 (0.747–3.039) | ||
Improved | 0.410 (0.193–0.868) | 0.020 | Extent of gastrectomy | 0.008 | |
Worse | 4.174 (1.255–13.881) | 0.020 | TG | 1 | |
NA | 0.856 (0.446–1.646) | 0.642 | DG | 0.521 (0.322–0.842) | |
Change in CA19–9 level | 0.399 | Extent of LND | 0.402 | ||
Stable | 1 | < D2 | 1 | ||
Improved | 1.020 (0.437–2.381) | 0.963 | ≥ D2 | 0.802 (0.480–1.343) | |
Worse | 0.907 (0.282–2.911) | 0.869 | Complete Macroscopic Resection | < 0.001 | |
NA | 0.580 (0.309–1.089) | 0.090 | Yes | 1 | |
Pre_op cT stage | 0.069 | No | 2.348 (1.471–3.748) | ||
Serosa negative | 1 | pT stage | 0.002 | ||
Serosa positive | 1.537 (0.967–2.444) | Serosa negative (pT1–3) | 1 | ||
Pre_op cN stage | 0.567 | Serosa positive (pT4a/b) | 2.109 (1.311–3.393) | ||
N0/N1 | 1 | pN stage | 0.121 | ||
N2/N3 | 1.155 (0.705–1.894) | pN0/N1 | 1 | ||
Time interval to surgery | 0.926 | pN2/N3 | 1.480 (0.901–2.430) | ||
≤ 24 weeks | 1 | Lauren classification | 0.013 | ||
> 24 weeks | 0.926 (0.584–1.468) | Intestinal | 1 | ||
Diffuse | 1.960 (1.204–3.190) | 0.007 | |||
Others | 0.867 (0.361–2.079) | 0.748 | |||
Postoperative chemotherapy | 0.172 | ||||
No | 1 | ||||
Yes | 1.629 (0.809–3.281) |